LifeStance Health Group Inc (NASDAQ:LFST) does about 2.00M shares in volume on a normal day but saw 3797644 shares change hands in the recent trading day. The company now has a market cap of 2.36B USD. Its current market price is $6.06, marking an increase of 10.38% compared to the previous close of $5.49. The 52 week high reached by this stock is $8.61 whilst the lowest price level in 52 weeks is $4.64.
The consensus objective for the share price is $8.86, suggesting that the stock has a potential upside of 31.6% over the period.
FactSet Research has provided data showing that 4 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 3 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on May 27, 2025 when UBS upgraded the stock to “Buy” and issued a price target of $8.50. Canaccord Genuity initiated its price target at $8.
The current price level is 0.76%, -5.35%, and -13.39% away from its SMA20, SMA50, and SMA200 respectively, with the LFST price moving above the 50-day SMA on current market day. LifeStance Health Group Inc (LFST) stock is up 3.77% over the week and -7.20% over the past month. Its price is -17.77% year-to-date and 4.30% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0.03 and 0.16 for whole year. Expected sales for next quarter are $359.16M, which analysts say will come at $1.41B for the current fiscal year and next year at $1.61B. In addition, estimates put the company’s current quarterly revenue at an average of $346.2M.
To reach the target analysts have set, the stock logically needs to grow 31.6 percent from here.
Outstanding shares total 388.83M with insiders holding 8.14% of the shares and institutional holders owning 93.21% of the company’s common stock. The company has a return on investment of -1.89% and return on equity of -2.47%. The forward price to earnings ratio is 163.17. The beta has a value of 1.24. Price to book ratio is 1.62 and price to sales ratio is 1.84.
